

## Original Article

†Graham K Murray and Marta Di Forti equally contributed to the supervision of the work and are joint last names.

**Cite this article:** Tripoli G *et al* (2020). Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. *Psychological Medicine* 1–11. <https://doi.org/10.1017/S003329171900357X>

Received: 20 May 2019

Revised: 7 October 2019

Accepted: 21 November 2019

### Key words:


First episode psychosis; IQ; jumping to conclusions; polygenic risk score; psychotic-like experiences; symptom dimensions

### Author for correspondence:

Giada Tripoli, E-mail: [giada.tripoli@kcl.ac.uk](mailto:giada.tripoli@kcl.ac.uk)

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study

Giada Tripoli<sup>1</sup> , Diego Quattrone<sup>2,3,4</sup>, Laura Ferraro<sup>5</sup>, Charlotte Gayer-Anderson<sup>6</sup>, Victoria Rodriguez<sup>1</sup>, Caterina La Cascia<sup>5</sup>, Daniele La Barbera<sup>5</sup>, Crocettarachele Sartorio<sup>5</sup>, Fabio Seminerio<sup>5</sup>, Ilaria Tarricone<sup>7</sup>, Domenico Berardi<sup>7</sup>, Andrei Szöke<sup>8</sup>, Celso Arango<sup>9</sup>, Andrea Tortelli<sup>10</sup>, Pierre-Michel Llorca<sup>11</sup>, Lieuwe de Haan<sup>12</sup>, Eva Velthorst<sup>12,13</sup>, Julio Bobes<sup>14</sup>, Miguel Bernardo<sup>15</sup>, Julio Sanjuán<sup>16</sup>, Jose Luis Santos<sup>17</sup>, Manuel Arrojo<sup>18</sup>, Cristina Marta Del-Ben<sup>19</sup>, Paulo Rossi Menezes<sup>20</sup>, Jean-Paul Selten<sup>21,22</sup>, EU-GEI WP2 Group, Peter B. Jones<sup>23,24</sup>, Hannah E Jongsma<sup>25</sup>, James B Kirkbride<sup>25</sup>, Antonio Lasalvia<sup>26</sup>, Sarah Tosato<sup>27</sup>, Alex Richards<sup>28</sup>, Michael O'Donovan<sup>28</sup>, Bart PF Rutten<sup>22</sup>, Jim van Os<sup>1,22,29</sup>, Craig Morgan<sup>6</sup>, Pak C Sham<sup>2,30</sup>, Robin M. Murray<sup>1</sup>, Graham K. Murray<sup>23,24,†</sup> and Marta Di Forti<sup>2,3,4,†</sup>

<sup>1</sup>Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK; <sup>2</sup>Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK; <sup>3</sup>National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; <sup>4</sup>South London and Maudsley NHS Mental Health Foundation Trust, London, UK; <sup>5</sup>Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Via G. La Loggia 1, 90129 Palermo, Italy; <sup>6</sup>Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK; <sup>7</sup>Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy; <sup>8</sup>INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France; <sup>9</sup>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain; <sup>10</sup>Etablissement Public de Santé Maison Blanche, Paris 75020, France; <sup>11</sup>Université Clermont Auvergne, EA 7280, Clermont-Ferrand 63000, France; <sup>12</sup>Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands; <sup>13</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA; <sup>14</sup>Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Julián Clavería s/n, 33006 Oviedo, Spain; <sup>15</sup>Barcelona Clinic Schizophrenia Unit, Department of Medicine, Neuroscience Institute, Hospital clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; <sup>16</sup>Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco Ibáñez 15, 46010 Valencia, Spain; <sup>17</sup>Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", C/Hermanidad de Donantes de Sangre, 16002 Cuenca, Spain; <sup>18</sup>Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain; <sup>19</sup>Division of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil; <sup>20</sup>Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; <sup>21</sup>Rivierduinen Institute for Mental Health Care, Sandiforddreef 19, 2333 ZZ Leiden, The Netherlands; <sup>22</sup>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands; <sup>23</sup>Department of Psychiatry, University of Cambridge, Cambridge, UK; <sup>24</sup>CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, CB21 5EF, UK; <sup>25</sup>PsyLife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road London, W1T 7NF, UK; <sup>26</sup>Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; <sup>27</sup>Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy; <sup>28</sup>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, CF24 4HQ, UK; <sup>29</sup>Department of Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands and <sup>30</sup>Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

## Abstract

**Background.** The 'jumping to conclusions' (JTC) bias is associated with both psychosis and general cognition but their relationship is unclear. In this study, we set out to clarify the relationship between the JTC bias, IQ, psychosis and polygenic liability to schizophrenia and IQ.

**Methods.** A total of 817 first episode psychosis patients and 1294 population-based controls completed assessments of general intelligence (IQ), and JTC, and provided blood or saliva samples from which we extracted DNA and computed polygenic risk scores for IQ and schizophrenia. **Results.** The estimated proportion of the total effect of case/control differences on JTC mediated by IQ was 79%. Schizophrenia polygenic risk score was non-significantly associated with a higher number of beads drawn ( $B = 0.47$ , 95% CI  $-0.21$  to  $1.16$ ,  $p = 0.17$ ); whereas IQ PRS ( $B = 0.51$ , 95% CI  $0.25$ – $0.76$ ,  $p < 0.001$ ) significantly predicted the number of beads drawn, and was thus associated with reduced JTC bias. The JTC was more strongly associated with the higher level of psychotic-like experiences (PLEs) in controls, including after controlling for IQ ( $B = -1.7$ , 95% CI  $-2.8$  to  $-0.5$ ,  $p = 0.006$ ), but did not relate to delusions in patients. **Conclusions.** Our findings suggest that the JTC reasoning bias in psychosis might not be a specific cognitive deficit but rather a manifestation or consequence, of general cognitive impairment. Whereas, in the general population, the JTC bias is related to PLEs, independent of IQ. The work has the potential to inform interventions targeting cognitive biases in early psychosis.

## Introduction

Jumping to conclusions (JTC) is a well-established reasoning and data gathering bias found in patients with psychosis (Dudley, Taylor, Wickham, & Hutton, 2016; Garety & Freeman, 2013; So, Siu, Wong, Chan, & Garety, 2016). It is usually measured by a reasoning task based on a Bayesian model of probabilistic inference known as the 'beads task' (Dudley, John, Young, & Over, 1997; Huq, Garety, & Hemsley, 1988).

Early work investigating reasoning bias through beads in jars paradigm focused on the association with delusions, finding that patients with delusions tend to require fewer beads to reach a decision than would be expected following Bayesian norms (Huq et al., 1988). In this respect, it has been suggested that data-gathering bias represents a key cognitive component in delusion formation and maintenance (Garety & Freeman, 1999). Although most of the studies endorsing this association used a cross-sectional design, comparing those with and without delusions in samples of patients with schizophrenia or other psychoses (Freeman et al., 2014; Garety et al., 2013), meta-analyses mostly found a weak association with delusions, yet a clear association with psychosis (Dudley et al., 2016; Fine, Gardner, Craigie, & Gold, 2007; Ross, McKay, Coltheart, & Langdon, 2015; So et al., 2016). Moreover, JTC was found not only in non-delusional and remitted patients with schizophrenia, but also in individuals at clinical high risk and first-degree relatives (Broome et al., 2007; Menon, Pomarol-Clotet, McKenna, & McCarthy, 2006; Moritz & Woodward, 2005; Peters & Garety, 2006; Van Dael et al., 2005).

Overall, these findings suggest that JTC could play a role in the liability for psychotic disorders, perhaps serving as an endophenotype associated with the genetic risk. As a highly heritable and polygenic disorder, many common genetic variants contribute to the risk of schizophrenia, which can be summarised into an individual polygenic risk score (PRS) (Purcell et al., 2009; Schizophrenia Working Group of the Psychiatric Genomics, 2014). Genome-wide association studies (GWAS) have found a significant genetic overlap between cognition and schizophrenia (Mistry, Harrison, Smith, Escott-Price, & Zammit, 2018; Ohi et al., 2018; Shafee et al., 2018), and a recent study by Touloupoulou (Touloupoulou et al., 2018) showed that the variance in schizophrenia liability explained by PRS was partially mediated through cognitive deficit. Despite a large body of literature on the JTC bias describing it as a potential intermediate phenotype, to date there has been no investigation into the possible genetic

overlap with psychosis through the PRS strategy. Nonetheless, there is a considerable amount of literature suggesting a link between JTC and cognitive functions. Cross-sectional studies on both recent onset psychosis and schizophrenia suggest that patients who present with neuropsychological deficits, especially involving executive functions, display more tendency to jump to conclusions (Garety et al., 2013; González et al., 2018). Those findings appear to be corroborated by the study of Lunt (Lunt et al., 2012) where JTC bias was found to be more prominent in individuals with prefrontal lesions, especially on the left side of the cortex, compared with controls. Woodward (Woodward, Mizrahi, Menon, & Christensen, 2009), using a principal component analysis (PCA) in a sample of inpatients with schizophrenia found that neuropsychological functions and JTC loaded on the same factor. Similar findings were obtained in a confirmatory factor analysis on psychotic patients with delusions and controls (Bentall et al., 2009). Interestingly in the latter, when general cognitive functioning was included in the model, the association between paranoia and JTC no longer held. In their study comparing patients with delusions, remitted patients with schizophrenia, and controls, Lincoln (Lincoln, Ziegler, Mehl, & Rief, 2010) found that, after taking intelligence into account, not only the association between JTC and delusions disappeared, but the group effect on the JTC bias was not detected any longer. Likewise, general intelligence affected statistically the relation between JTC and psychosis liability in the van Dael study (Van Dael et al., 2005). Lower IQ was also found associated with JTC in first episode psychosis (FEP) (Catalan et al., 2015; Falcone et al., 2015). Nonetheless, other studies on early psychosis did not detect any association with cognition, possibly due to the small sample size (Langdon, Still, Connors, Ward, & Catts, 2014; Ormrod et al., 2012).

Thus, although many studies highlighted that JTC is strongly associated with delusions, and more broadly with psychosis, this association seems to be affected by the general cognitive function. To address this question robustly requires a large sample size, whereas most previous studies of JTC in psychiatry have had moderate sample sizes of between 20 and 100 patients. Therefore, we used data from the large multi-country European Network of national schizophrenia networks studying the Gene-Environment Interactions (EUGEI) case-control study of FEP to investigate whether IQ plays a role as mediator in the pathway between the bias and the disorder. We also aimed to investigate whether JTC is associated with the liability for psychotic disorders and/or liability to general intellectual function.

Therefore, in this study we aim to test the following predictions:

- (1) The JTC bias will be best predicted by clinical status through IQ mediation;
- (2) The JTC bias will be predicted by the polygenic risk score for schizophrenia (SZ PRS) and by the polygenic risk score for IQ (IQ PRS).
- (3) The JTC bias will be predicted by delusions in patients and psychotic-like experiences (PLEs) in controls.

## Methods

### Participants

Participants were recruited and assessed as part of the incidence and first episode case-control study, conducted as part of the EU-GEI programme (Di Forti et al., 2019; Gayer-Anderson, 2019; Jongsma et al., 2018). The study was designed to investigate risk factors for psychotic disorders between 1 May 2010 and 1 April 2015 in 17 sites ranging from rural to urban areas in England, France, the Netherlands, Italy, Spain and Brazil.

All participants provided informed, written consent following full explanation of the study. Ethical approval was provided by relevant research ethics committees in each of the study sites. Patients with a FEP were recruited through regular checks across the 17 defined catchment areas Mental Health services to identify all individuals aged 18–64 years who presented with a FEP during the study period. Patients were included if they met the following criteria during the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a clinical diagnosis for an untreated FEP, even if longstanding [International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes F20–F33] and (c) resident within the catchment area at FEP. Exclusion criteria are: (a) previous contact with psychiatric services for psychosis; (b) psychotic symptoms with any evidence of organic causation and (c) transient psychotic symptoms resulting from acute intoxication (ICD-10: F1x.5).

Inclusion criteria for controls are: (a) aged between 18 and 64 years; (b) resident within a clearly defined catchment area at the time of consent into the study; (c) sufficient command of the primary language at each site to complete assessments and (d) no current or past psychotic disorder. To select a population-based sample of controls broadly representative of local populations in relation to age, gender and ethnicity, a mixture of random and quota sampling was adopted. Quotas for control recruitment were based on the most accurate local demographic data available, and then filled using a variety of recruitment methods, including through: (1) random sampling from lists of all postal addresses (e.g. in London); (2) stratified random sampling via general practice (GP) lists (e.g. in London and Cambridge) from randomly selected surgeries and (3) *ad hoc* approaches (e.g. internet and newspaper adverts, leaflets at local stations, shops and job centres).

### Measures

Detailed information on age, sex, self-reported ethnicity, level of education and social networks was collected using the Medical Research Council (MRC) Sociodemographic Schedule (Mallett, 1997).


The short form of the WAIS III was administered as an indicator of general cognitive ability (IQ) and includes the following subtests: information (verbal comprehension), block design (reasoning and problem solving), arithmetic (working memory) and digit symbol-coding (processing speed). This short form has been shown to give reliable and valid estimates of Full-Scale IQ in schizophrenia (Velthorst et al., 2013).

Following instructions and practice, the JTC bias was assessed using a single trial of the computerised 60:40 version of the beads task. In this task, there are two jars containing coloured beads with a complementary ratio (60:40). One jar is chosen, and beads are drawn one at a time and shown to the participants following the pattern: BRRBBRBBBBRBBBBRRBRRB, where B indicates a blue bead and R indicates red. After each draw they are required to either decide from which jar the beads have come or defer the decision (up to a maximum of 20 beads). This single-trial experiment was terminated when the participant made the decision of which jar the beads were being drawn from. The key outcome variable employed as an index of the JTC bias was the number of 'Draws-To-Decision' (DTD); the lower the DTD, the greater the JTC bias. The binary JTC variable based on the choice of 2 or less beads before answering the task was also employed.

Psychopathology was assessed using the OPERational CRITera system (OPCRIT) (McGuffin, Farmer, & Harvey, 1991). Item response modelling was previously used to develop a bi-factor model composed of general and specific dimensions of psychotic symptoms, which include the positive symptom dimension (delusion and hallucination items) (Quattrone et al., 2018). For the purposes of the present work, we adapted the previous method to estimate an alternative bi-factor model comprising two discrete hallucination and delusion symptom dimensions, instead of a single positive symptom dimension. We assessed PLEs in controls through the Community Assessment of Psychic Experience (CAPE) (Stefanis et al., 2002) positive dimension score (online Supplementary Table S1). The CAPE is a self-report questionnaire with good reliability for all the languages spoken in the EUGEI catchment areas (<http://www.cape42.homestead.com/>).

### Polygenic risk scores

The case-control genotyped WP2 EUGEI sample ( $N=2169$ ; cases' samples  $N=920$ , controls' samples  $N=1248$ ) included DNA extracted from blood ( $N=1857$ ) or saliva ( $N=312$ ). The samples were genotyped at the MRC Centre for Neuropsychiatric Genetics and Genomics in Cardiff (UK) using a custom Illumina HumanCoreExome-24 BeadChip genotyping array covering 570 038 genetic variants. After genotype Quality Control, we excluded SNPs with minor allele frequency  $<0.5\%$ , Hardy Weinberg Equilibrium  $p < 10^{-6}$ , missingness  $>2\%$ . After sample Quality Control, we excluded samples with  $>2\%$  missingness, heterozygosity Fhet  $>0.14$  or  $<-0.11$ , who presented genotype-phenotype sex mismatch or who clustered with homogenous black ancestry in PCA analysis ( $N=170$ ). The final sample was composed of 1720 individuals (1112 of European ethnicity, 608 of any other ethnicities but not black African), of which 1041 controls and 679 patients. Imputation was performed through the Michigan Imputation Server, using the Haplotype Reference Consortium reference panel with the Eagle software for estimating haplotype phase, and Minimac3 for genotype imputation (Das et al., 2016; Loh et al., 2016; McCarthy et al., 2016). The imputed variants with  $r^2 < 0.6$ , MAF  $<0.1\%$  or missingness  $>1\%$  were excluded.



**Fig. 1.** Mediation model between caseness (IV), IQ (MV) and DTD (DV).  
Note: DTD, draws-to-decision; IQ, intelligent quotient.

The PRS for schizophrenia and IQ was built using, as training data sets, the results from the last available mega-analysis from the Psychiatric Genomics Consortium (PGC) (Schizophrenia Working Group of the Psychiatric Genomics, 2014) and Savage et al. (2018) respectively. In PRSice, individuals' number of risk alleles in the target sample was weighted by the log odds ratio from the discovery samples and summed into the PRSs at a 0.05 SNPs Pt-thresholds (apriori selected). We excluded people of homogeneous African ancestry since in this population the SZ PRS from the PGC2 we calculated, as reported by other studies (Vassos et al., 2017), failed to explain a significant proportion of the variance ( $R^2 = 1.1\%$ ,  $p = 0.004$ ).

### Design and procedure

The EU-GEI study WP2 employed a case-control design collecting data with an extensive battery of demographic, clinical, social and biological measures (Core assessment); psychological measures, and cognitive tasks. All EU-GEI WP2 participants with JTC and IQ data were included in the current study. All the researchers involved in administrating the assessments undertook a training organised by a technical working committee of the overall EU-GEI study (Work Package 11) at the beginning and throughout the study. Inter-rater reliability was assessed annually to warrant the comparability of procedures and methods across sites.

### Statistical analysis

Analyses were conducted in STATA 15 (StataCorp., 2017). Preliminary descriptive analyses were performed using  $\chi^2$  and  $t$  tests to examine the differences in age, sex, ethnicity, level of education, IQ and DTD between cases and controls. To test possible statistical mediation by IQ as intervening variable between case/control status and DTD, we applied Baron and Kenny's procedure (1986). According to the authors, a mediation can be established

when (1) variations in the independent variable (IV) significantly account for variations in the dependent variable (DV); (2) variations in the IV significantly account for variations in the mediator variable (Rimvall et al.); (3) variations in the MV significantly account for variations in the DV and (4) a previous significant effect of IV on DV is markedly decreased after controlling for MV. Perfect mediation occurs when the independent variable has no effect after controlling for the mediator (Baron & Kenny, 1986).

The STATA 15 *sgmediation* command was used to perform three OLS regressions according to Baron and Kenny's steps as follows: (1) DTD (DV) regressed on case/control status (IV) – Path c, (2) IQ (MV) regressed on case/control status (IV) – Path a, (3) DTD (DV) regressed on IQ (MV) and case/control status (IV) – Path b and c' (Fig. 1). All the steps included as covariates age, sex, ethnicity and country. Furthermore, to generate confidence intervals for the indirect effect, 5000 bootstrap replications were performed (Preacher & Hayes, 2008) and a non-parametric confidence interval based on the empirical sampling distributions was constructed.

To investigate whether JTC was associated with the liability for psychotic disorders and general intelligence, we firstly tested the accuracy of the PRSs to predict their primary phenotypes (case/control status and IQ) in our sample through logistic and linear regression models respectively. Then, we built and compared linear regression models regressing DTD on (1) case/control status, controlling for age, sex and 20 principal components for population stratification; (2) SZ PRS and (3) IQ PRS, adjusting for case/control status, age, sex, IQ and 20 principal components for population stratification.

Linear regression models were built to test the effect of the delusion symptom dimension on DTD, adding in the second step as covariates age, sex, ethnicity, IQ and country, in patients. We ran the same models in controls using the CAPE positive score as a predictor.

We repeated all the analyses using as a secondary outcome the binary variable JTC/no JTC (see online supplementary material).




Fig. 2. FEP recruitment flowchart.

Table 1. Demographic and cognitive characteristics of the sample included in the analysis

	Controls <i>N</i> = 1294	FEP <i>N</i> = 817	df	Test statistics	<i>p</i> value
Age (mean; s.d.)	36.2 (13.1)	30.6 (10.4)	2109	<i>T</i> = 10.3	<i>p</i> < 0.001
Sex (male %; <i>N</i> )	47.5 (615)	61.2 (500)	1	$\chi^2 = 37.6$	<i>p</i> < 0.001
Ethnicity (%; <i>N</i> )					
White	77.9 (1009)	65.1 (531)	6	$\chi^2 = 48.3$	<i>p</i> < 0.001
Black	8.4 (109)	14.9 (122)			
Mixed	7.9 (102)	10.5 (86)			
Asian	2.3 (30)	2.8 (23)			
North African	1.6 (21)	4.0 (33)			
Other	1.8 (23)	2.6 (21)			
Education (%; <i>N</i> )					
Left school with no qualifications	4.5 (58)	15.2 (124)	3	$\chi^2 = 202.5$	<i>p</i> < 0.001
School with qualifications	13.3 (172)	26.6 (217)			
Tertiary & Vocational	42.9 (555)	41.9 (343)			
Undergraduate & Postgraduate	38.9 (503)	15.9 (130)			
Missing	0.5 (6)	0.4 (3)			
IQ (mean; s.d.)	102.6 (17.8)	85.2 (18.1)	2109	<i>T</i> = 21.8	<i>p</i> < 0.001
DTD (mean; s.d.)	4.9 (4.7)	3.7 (4.3)	2109	<i>T</i> = 5.5	<i>p</i> < 0.001

Note: DTD, draws-to-decision; IQ, intelligent quotient.

## Results

### Sample characteristics

Cases and controls recruited as part of the EU-GEI study were included in the current study if data on both Beads task and WAIS were available. This led to a sample of FEP cases = 817 and controls *N* = 1294 for the mediation analysis (Fig. 2).


Cases were more often younger (cases mean age =  $30.6 \pm 10.4$  v. controls mean age =  $36.2 \pm 13.1$ ;  $t = 10.3$ ,  $p < 0.001$ ), men [cases 61.2% (500) v. controls 47.5% (615);  $\chi^2_{(1)} = 37.6$ ,  $p < 0.001$ ] and from minority ethnic backgrounds ( $\chi^2_{(6)} = 48.3$ ,  $p < 0.001$ ) compared to controls (Table 1). The aforementioned differences

are those expected when comparing psychotic patients with the general population.

The analysis of PRSs was performed in a subsample of 519 FEP and 881 population controls with available GWAS data.

### Jumping to conclusions, psychosis and IQ

The results of the mediation model are displayed in Fig. 3. There was evidence of a negative association between caseness and DTD in path c [ $B = -1.4$  (0.2); 95% CI  $-1.8$  to  $-0.9$ ;  $p < 0.001$ ; adjusted  $R^2 = 8\%$ ]; as well as with IQ in Path a [ $B = -16.7$  (0.8); 95% CI  $-18.24$  to  $-15.10$ ;  $p < 0.001$ ]. Path b showed that higher IQ scores



**Fig. 3.** Mediation results.

Note: DTD, draws-to decision; IQ, intelligent quotient.  
 $^{**}p < 0.001$ .

were significantly related to more DTD [ $B = 0.06$  (0.01); 95% CI 0.05–0.07;  $p < 0.001$ ]. The direct effect of case status on DTD displayed in path  $c'$  markedly dropped from  $-1.4$  to  $-0.3$  and was no longer statistically significant [ $B = -0.3$  (0.2); 95% CI  $-0.7$  to  $0.1$ ;  $p = 0.19$ ]. The estimated proportion of the total effect of case status on DTD mediated by IQ was 79% and the variance explained by the model rose to 14%. After performing 5000 bootstrap replications, the estimated indirect effect remained statistically significant [ $B = -0.2$  (0.02); 95% CI  $-0.3$  to  $-0.2$ ].

#### Jumping to conclusions, SZ PRS and IQ PRS

Sz PRS was a predictor for case status (OR 5.3, 95% CI 3.7–7.5,  $p < 0.001$ ), explaining 7% of the variance, as well as IQ PRS for IQ ( $B = 3.9$ , 95% CI 2.9–4.9,  $p < 0.001$ ), accounting for 14% of the variance. As is shown in Table 2, SZ PRS was not significantly associated with JTC, but in fact was non-significantly associated with increased numbers of beads drawn ( $B = 0.5$ , 95% CI  $-0.2$  to  $1.2$ ,  $p = 0.17$ ); whereas IQ PRS was positively associated with the number of beads drawn ( $B = 0.5$ , 95% CI 0.3–0.8,  $p < 0.001$ ). When adding the IQ PRS to case-control status as a predictor of DTD, the variance explained rose to 10%, of which 1% was due to the PRS term. This relationship held even after adjusting for IQ ( $B = 0.3$ , 95% CI 0.1–0.6,  $p = 0.017$ ).

#### Jumping to conclusions, positive symptoms and psychotic-like experiences

The delusion symptom dimension was positively associated with DTD ( $B = 0.4$ , 95% CI 0.1–0.8,  $p = 0.013$ ), although the association became less accurate when adjusting for age, sex, ethnicity, IQ and country, with the 95% confidence interval including zero effect ( $B = 0.1$ , 95% CI  $-0.2$  to  $0.4$ ,  $p = 0.531$ ). The hallucination dimension was not a robust predictor of DTD, whether or not covariates were modelled (unadjusted  $B = -0.3$ , 95% CI  $-0.7$  to

$0.1$ ,  $p = 0.089$ ). Whereas the CAPE positive symptoms score was negatively associated with the number of beads requested by controls ( $B = -2.5$ , 95% CI  $-3.8$  to  $-1.3$ ,  $p < 0.001$ ), which remained significant even after controlling for age, sex, ethnicity, IQ and country ( $B = -1.7$ , 95% CI  $-2.8$  to  $-0.5$ ,  $p = 0.006$ ).

#### Discussion

The present study was conducted to investigate the relation between the JTC bias and general cognitive ability in the first episode psychotic patients. We used the largest to date incidence sample of FEP patients and population-based controls with available data on the JTC bias to address the question: is the link between the bias and the disorder better explained by the mediation of IQ? Moreover, this is the first study to test the association between JTC and genetic susceptibility to schizophrenia.

We found that IQ is accountable for about 80% of the effect of caseness on JTC. The data in fact indicated that case control differences in JTC were not only partially mediated by IQ but were fully mediated by IQ. In other words, the JTC bias in FEP might not be an independent deficit but part of general cognitive impairment. We obtained similar results also using the binary outcome JTC yes/no (see online supplementary material). Previous studies focusing on different explanations between the JTC bias and psychotic disorder suggested that deluded patients tend to request less information because sampling itself might be experienced as more costly than it would be by healthy people (Ermakova et al., 2018; Moutoussis, Bentall, El-Deredy, & Dayan, 2011). Although patients at onset seem to adjust their strategy according to the cost of sampling where clearly stated and show more bias to sample less information in the classic task, general cognitive ability still plays an important role in their decision-making behaviour (Ermakova et al., 2018; Moutoussis et al., 2011). Indeed, the inclusion of general cognitive ability in the relation between JTC and clinical status was reported to

**Table 2.** Linear regressions of PRS predicting DTD

	Draws-to-decision (outcome)				
	B/s.e.	p value	95% CI	R <sup>2</sup> (%)	Adj R <sup>2</sup> (%)
Case v. Control <sup>a</sup>	−0.9/0.3	0.001	−1.4 to −0.4	9	8
SZ PRS <sup>a</sup>	0.2/0.3	0.64	−0.5 to 0.8	9	7
SZ PRS <sup>b</sup>	0.5/0.4	0.17	−0.2 to 1.2	9	8
SZ PRS <sup>c</sup>	0.4/0.3	0.23	−0.3 to 1.1	13	11
IQ PRS <sup>a</sup>	0.5/0.1	<0.001	0.3–0.8	10	8
IQ PRS <sup>b</sup>	0.5/0.1	<0.001	0.2–0.7	10	9
IQ PRS <sup>c</sup>	0.3/0.1	0.017	0.1–0.6	13	11

SZ, schizophrenia; PRS, polygenic risk score; IQ, intelligent quotient.

<sup>a</sup>Adjusted for age, sex and 20 principal components for population stratification.

<sup>b</sup>Adjusted for case/control, age, sex and 20 principal components for population stratification.

<sup>c</sup>Adjusted for case/control, age, sex, IQ and 20 principal components for population stratification.

substantially decrease or nullify a prior significant association (Falcone et al., 2015; Lincoln et al., 2010; Van Dael et al., 2005). Our results are consistent with these studies and provide the first evidence that the genetic variants associated with IQ are negatively correlated with JTC, therefore endorsing the hypothesis that cognition as endophenotype mediates the relation between the bias and the liability for psychotic disorders.

In our study SZ PRS was not significantly associated with JTC. However, as the PRS technique is based on contribution of common SNPs variation to genetic risk, its detection is strictly dependent on statistical power (Smoller et al., 2019; Wray et al., 2014). Although GWAS studies on schizophrenia have already identified a substantial number of genetic variants by increasing sample size (Schizophrenia Working Group of the Psychiatric Genomics, 2014), SZ PRS still accounts for 7% of the variance in schizophrenia liability, as we also found in our sample. Whereas, IQ PRS is based on a far larger GWAS (Savage et al., 2018), explaining as twice the variance as SZ PRS in our study. We note that the effect sizes (quantified by estimated regression parameters) between the schizophrenia PRS and DTD was similar in size to, but, *contrary to expectation, in the same direction as*, the effect size between the IQ PRS and DTD (but note the former association was non-significant). Another possible explanation lies in the fact that JTC seems to be more associated with the continuous distribution of delusions rather than with schizophrenia *per se* (Broome et al., 2007; Menon et al., 2006; Moritz & Woodward, 2005; Peters & Garety, 2006; Van Dael et al., 2005). In fact, in a large case-control study on FEP patients carried out by Falcone et al. (2015), adjusting for IQ and working memory abolished the relation between JTC and clinical status, but the association between JTC and delusion severity remained. Perhaps building a PRS based on the positive symptom dimension or delusions would be more associated with the bias. However, in line with a recent finding that patients with higher delusion severity may have a tendency to *increased* information seeking (Baker, Horga, Konova, & Daw, 2019), we found delusions were associated with higher number of beads drawn, although with a small effect size and attenuation after adjustment. Whereas, the direction of the effect of PLE on the number of beads requested by controls was expected (Freeman, Pugh, & Garety, 2008; Reininghaus et al., 2018; Ross et al., 2015), and more interestingly independent from IQ. Perhaps in the absence of general cognitive

impairment, the tendency to JTC contributes to PLE independent of general intellectual function, whereas in the context of disorder with general cognitive impairment, the JTC bias may not specifically relate to the pathogenesis of psychosis. Future research is warranted to further address this relation.

### Strengths and limitations

Our study has several advantages. These include the large sample size, the study of patients at the onset of illness and population controls. There are limitations to our study. Although the sample size is several times larger than any individual previous study, it is still modest by genomic standards. We only included a single trial of the task, as previous research has indicated that the measure of DTD is very reliable over trials (Ermakova et al., 2018; Ermakova, Ramachandra, Corlett, Fletcher, & Murray, 2014), to facilitate data collection in this large multi-centre study. It can be argued that only performing one trial using the higher cognitive demanding 60:40 version could capture more miscomprehension of the task rather than truly the bias, resulting in overestimating its presence (Balzan, Delfabbro, & Galletly, 2012a; Balzan, Delfabbro, Galletly, & Woodward, 2012b). However, the beads task employed in the study included a practice exercise before the trial. Moreover, the difference between means of beads requested by cases and controls in our study was smaller than reported in a meta-analysis on 55 studies (1.1 v. 1.4 to 1.7) (Dudley et al., 2016). Nonetheless, future research is warranted to explore more specific cognitive mediation, such as working memory and executive functions (Falcone et al., 2015; Garety et al., 2013; González et al., 2018), between JTC and psychosis using more trials of the Beads Task. The inclusion of more trials in future studies would permit a more detailed interrogation of the task (Ermakova et al., 2014, 2018). For example, the use of multiple trials allows modelling of latent variables such as the probing of the distinct roles of cognitive noise and alterations in the perceived 'cost' of information sampling, which may have partially distinct genetic bases. We did not measure delusions with a symptom severity rating scale, but rather calculated a measure of a delusions factor using an item-response analysis from OPCRIT identified symptoms, so we caution over-interpretation of the analysis of the relation between DTD and delusions within the patient group. The CAPE self-report questionnaire was only

completed by controls, in accordance with its original design for use in community samples.

### Implications

Our results suggested that the tendency to jump to conclusions may be associated with psychosis liability via a general cognitive pathway. In fact, improvements on data-gathering resulting in delayed decision making seem to be driven by cognitive mechanisms as shown in Randomised Control Trials comparing Metacognitive Training (MCT) – which JTC is a core module – with Cognitive Remediation Therapy in schizophrenia spectrum disorders (Moritz *et al.*, 2013, 2014). However, psychosis liability does not necessarily translate to other outcomes of interest in psychosis, such as prognosis; for example, Andreou (Andreou *et al.*, 2014) using the same sample as Moritz (Moritz *et al.*, 2013) found that JTC was the only significant predictor of improvement in vocational status at 6 months follow up in terms of probability of regaining full employment status. Similarly, Dudley (Dudley *et al.*, 2013) found that patients who displayed stable JTC after 2 years showed an increase in symptomatology, whereas stable non-jumpers showed a reduction, as did those who switched to be a non-jumper. Although the aforementioned study did not account for cognition, results are in line with the literature showing the efficacy of MCT on delusion severity and general functioning up to 3-year-follow-up (Favrod *et al.*, 2014; Moritz *et al.*, 2013, 2014), and even in individuals with recent onset of psychosis (Ochoa *et al.*, 2017). Moreover, a recent study (Rodriguez *et al.*, 2018) which followed up the FEP sample reported in Falcone *et al.* (2015), showed that JTC at baseline predicted poorer outcome in terms of more days of hospitalisation, compulsory admissions and higher risk of police intervention at 4-year follow-up, even after controlling for IQ.

Thus, although JTC bias might be secondary to a cognitive impairment in the early stages of psychosis, JTC could play an important role in both delusions' maintenance and clinical outcome. Therefore, targeting this bias along with other cognitive deficits in psychosis therapies and interventions might represent a useful strategy to improve outcomes (Andreou *et al.*, 2014; Moritz *et al.*, 2013). However, our data suggest that specific interventions to address this particular cognitive bias in terms of psychosis liability may not provide any advantage over and above cognitive remediation of general cognitive deficits (Wykes *et al.*, 2007).

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S003329171900357X>

**Acknowledgements.** This study was funded by the Medical Research Council, the European Community's Seventh Framework Program grant [agreement HEALTH-F2-2009-241909 (Project EU-GEI)], São Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London, the NIHR BRC at University College London and the Wellcome Trust (grant 101272/Z/12/Z).

**Conflict of interest.** The authors have no conflicts of interest to declare in relation to the work presented in this paper.

**Group information.** The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions WP2 Group members includes:

**Amoretti, Silvia**, PhD Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain, CIBERSAM, Spain; **Andreu-Bernabeu, Álvaro**, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain; **Baudin, Grégoire**, MSc, AP-HP, Groupe Hospitalier 'Mondor,' Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France; **Beards, Stephanie**, PhD, Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London, England; **Bonetto, Chiara**, PhD, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy; **Bonora, Elena**, PhD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy; **Cabrera, Bibiana**, MSc, PhD, Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain, CIBERSAM, Spain; **Carracedo, Angel**, MD, PhD, Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, Santiago de Compostela, Spain; **Charpeaud, Thomas**, MD, Fondation Fondamental, Créteil, France, CMP B CHU, Clermont Ferrand, France, and Université Clermont Auvergne, Clermont-Ferrand, France; **Costas, Javier**, PhD, Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, Santiago de Compostela, Spain; **Cristofalo, Doriane**, MA, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy; **Cuadrado, Pedro**, MD, Villa de Vallecas Mental Health Department, Villa de Vallecas Mental Health Centre, Hospital Universitario Infanta Leonor/Hospital Virgen de la Torre, Madrid, Spain; **D'Andrea, Giuseppe**, MD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy; **Díaz-Caneja, Covadonga M**, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain; **Durán-Cutilla, Manuel**, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain; **Fraguas, David**, MD, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IISGM, School of Medicine, Universidad Complutense, Madrid, Spain; **Ferchiou, Aziz**, MD, AP-HP, Groupe Hospitalier 'Mondor,' Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France; **Franke, Nathalie**, MSc, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; **Frijda, Flora**, MSc, Etablissement Public de Santé Maison Blanche, Paris, France; **García Bernardo, Enrique**, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón (CIBERSAM), Madrid, Spain; **García-Portilla, Paz**, MD, PhD, Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain; **González Peñas, Javier**, PhD, Hospital Gregorio Marañón, IISGM, School of Medicine, Calle Dr Esquerdo, 46, Madrid 28007, Spain; **González, Emiliano**, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Hubbard, Kathryn**, MSc, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London; **Jamain, Stéphane**, PhD, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France, and Fondation Fondamental, Créteil, France; **Jiménez-López, Estela**, MSc, Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz,' Cuenca, Spain; **Leboyer, Marion**, MD, PhD, AP-HP, Groupe Hospitalier 'Mondor,' Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France, and Fondation Fondamental, Créteil, France; **López Montoya, Gonzalo**, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Lorente-Rovira, Esther**,



PhD, Department of Psychiatry, School of Medicine, Universidad de Valencia, CIBERSAM, Valencia, Spain; **Marcelino Loureiro, Camila**, MD, Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil, and Núcleo de Pesquisa em Saúde Mental Populacional, Universidade de São Paulo, São Paulo, Brasil; **Marrazzo, Giovanna**, MD, PhD, Unit of Psychiatry, 'P. Giaccone' General Hospital, Palermo, Italy; **Martínez Díaz-Caneja, Covadonga**, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, Madrid, Spain; **Matteis, Mario**, MD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Messchaert, Elles**, MSc, Rivierduinen Centre for Mental Health, Leiden, the Netherlands; **Mezquida, Gisela**, PhD, Centre for Biomedical Research in the Mental Health Network (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain; **Moltó, Ma Dolores**, Department of Genetics, University of Valencia, Campus of Burjassot, Biomedical Research Institute INCLIVA, Valencia, Spain, Centro de Investigación Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain; **Moreno, Carmen**, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Nacher Juan**, Neurobiology Unit, Department of Cell Biology, Interdisciplinary Research Structure for Biotechnology and Biomedicine (BIOTECMED), Universitat de València, Valencia, Spain, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM): Spanish National Network for Research in Mental Health, Madrid, Spain, Fundación Investigación Hospital Clínico de Valencia, INCLIVA, Valencia, Spain; **Olmeda, Ma Soledad**, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Madrid, Spain; **Parellada, Mara**, MD, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Pignon, Baptiste**, MD, AP-HP, Groupe Hospitalier 'Mondor,' Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, and Fondation Fondamental, Créteil, France; **Rapado, Marta**, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Richard, Jean-Romain**, MSc, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, and Fondation Fondamental, Créteil, France; **Rodríguez Solano, José Juan**, MD, Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor/Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, Madrid, Spain; **Roldán, Laura**, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, C/ Doctor Esquerdo 46, 28007 Madrid, Spain; **Ruggeri, Mirella**, MD, PhD, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy; **Sáiz, Pilar A**, MD, Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM, Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain; Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain; **Sánchez-Gutiérrez, Teresa**, PhD, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, C/Doctor Esquerdo 46, 28007 Madrid, Spain; **Sánchez, Emilio**, MD, Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM (CIBERSAM), Madrid, Spain; **Schürhoff, Franck**, MD, PhD, AP-HP, Groupe Hospitalier 'Mondor,' Pôle de Psychiatrie, Créteil, France, Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France, Faculté de Médecine, Université Paris-Est, Créteil, France, and Fondation Fondamental, Créteil, France; **Seri, Marco**, MD, Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy; **Shuhama, Rosana**, PhD, Departamento de Neurociências e Ciências do Comportamento, Faculdade

de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil, and Núcleo de Pesquisa em Saúde Mental Populacional, Universidade de São Paulo, São Paulo, Brasil; **Sideli, Lucia**, PhD, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Via G. La Loggia 1, 90129 Palermo, Italy; **Stilo, Simona A**, MD, PhD, Department of Health Service and Population Research, and Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London, England; **Termorshuizen, Fabian**, PhD, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, the Netherlands, and Rivierduinen Centre for Mental Health, Leiden, the Netherlands; **Tronche, Anne-Marie**, MD, Fondation Fondamental, Créteil, France, CMP B CHU, Clermont Ferrand, France, and Université Clermont Auvergne, Clermont-Ferrand, France; **van Dam, Daniella**, PhD, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; **van der Ven, Els**, PhD, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, the Netherlands, Rivierduinen Centre for Mental Health, Leiden, the Netherlands, and Mailman School of Public Health, Columbia University, New York, NY.

## References

- Andreou, C., Treszl, A., Roesch-Ely, D., Köther, U., Veckenstedt, R., & Moritz, S. (2014). Investigation of the role of the jumping-to-conclusions bias for short-term functional outcome in schizophrenia. *Psychiatry Research*, 218(3), 341–347.
- Baker, S. C., Horga, G., Konova, A. B., & Daw, N. D. (2019). A distinct inferential mechanism for delusions in schizophrenia. *Brain*, 142(6), 1797–1812. <https://doi.org/10.1093/brain/awz051>.
- Balzan, R., Delfabbro, P., & Galletly, C. (2012a). Delusion-proneness or miscomprehension? A re-examination of the jumping-to-conclusions bias. *Australian Journal of Psychology*, 64(2), 100–107.
- Balzan, R. P., Delfabbro, P. H., Galletly, C. A., & Woodward, T. S. (2012b). Over-adjustment or miscomprehension? A re-examination of the jumping to conclusions bias. *Australian & New Zealand Journal of Psychiatry*, 46(6), 532–540.
- Baron, R. M., & Kenny, D. A. (1986). The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. *Journal of Personality and Social Psychology*, 51(6), 1173–1182.
- Bentall, R. P., Rowse, G., Shryane, N., Kinderman, P., Howard, R., Blackwood, N. ... Corcoran, R. (2009). The cognitive and affective structure of paranoid delusions: A transdiagnostic investigation of patients with schizophrenia Spectrum disorders and depression. *Archives of General Psychiatry*, 66(3), 236–247.
- Broome, M. R., Johns, L., Valli, I., Woolley, J., Tabraham, P., Brett, C. ... McGuire, P. (2007). Delusion formation and reasoning biases in those at clinical high risk for psychosis. *The British Journal of Psychiatry*, 191(51), s38–s42.
- Catalan, A., Simons, C. J. P., Bustamante, S., Olazabal, N., Ruiz, E., Gonzalez de Artaza, M. ... Gonzalez-Torres, M. A. (2015). Data gathering bias: Trait vulnerability to psychotic symptoms? *PLoS ONE*, 10(7), e0132442.
- Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A. ... Fuchsberger, C. (2016). Next-generation genotype imputation service and methods. *Nature Genetics*, 48(10), 1284–1287.
- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H. ... the EU-GEI WP2 Group. (2019). The contribution of cannabis use to variation in incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. *The Lancet Psychiatry*, 6(5), 427–436.
- Dudley, R., Daley, K., Nicholson, M., Shaftoe, D., Spencer, H., Cavanagh, K., & Freeston, M. (2013). 'Jumping to conclusions' in first-episode psychosis: A longitudinal study. *British Journal of Clinical Psychology*, 52(4), 380–393.

- Dudley, R., Taylor, P., Wickham, S., & Hutton, P. (2016). Psychosis, delusions and the “jumping to conclusions” reasoning bias: A systematic review and meta-analysis. *Schizophrenia Bulletin*, 42(3), 652–665.
- Dudley, R. E., John, C. H., Young, A. W., & Over, D. E. (1997). Normal and abnormal reasoning in people with delusions. *The British Journal of Clinical Psychology*, 36(Pt 2), 243–258.
- Ermakova, A. O., Gileadi, N., Knolle, F., Justicia, A., Anderson, R., Fletcher, P. C. et al. (2018). Cost evaluation during decision-making in patients at early stages of psychosis. *Computational Psychiatry*, 3, 18–39.
- Ermakova, A. O., Ramachandra, P., Corlett, P. R., Fletcher, P. C., & Murray, G. K. (2014). Effects of methamphetamine administration on information gathering during probabilistic reasoning in healthy humans. *PLOS ONE*, 9(7), e102683.
- Falcone, M. A., Murray, R. M., Wiffen, B. D. R., O'Connor, J. A., Russo, M., Koliakou, A. ... Jolley, S. (2015). Jumping to conclusions, neuropsychological functioning, and delusional beliefs in first episode psychosis. *Schizophrenia Bulletin*, 41(2), 411–418.
- Favrod, J., Rexhaj, S., Bardy, S., Ferrari, P., Hayoz, C., Moritz, S. ... Bonsack, C. (2014). Sustained antipsychotic effect of metacognitive training in psychosis: A randomized-controlled study. *European Psychiatry*, 29(5), 275–281.
- Fine, C., Gardner, M., Craigie, J., & Gold, I. (2007). Hopping, skipping or jumping to conclusions? Clarifying the role of the JTC bias in delusions. *Cognitive Neuropsychiatry*, 12(1), 46–77.
- Freeman, D., Pugh, K., & Garety, P. (2008). Jumping to conclusions and paranoid ideation in the general population. *Schizophrenia Research*, 102(1–3), 254–260.
- Freeman, D., Startup, H., Dunn, G., Černis, E., Wingham, G., Pugh, K. ... Kingdon, D. (2014). Understanding jumping to conclusions in patients with persecutory delusions: Working memory and intolerance of uncertainty. *Psychological Medicine*, 44(14), 3017–3024.
- Garety, P., Joyce, E., Jolley, S., Emsley, R., Waller, H., Kuipers, E. ... Freeman, D. (2013). Neuropsychological functioning and jumping to conclusions in delusions. *Special Section: Negative Symptoms*, 150(2–3), 570–574.
- Garety, P. A., & Freeman, D. (1999). Cognitive approaches to delusions: A critical review of theories and evidence. *British Journal of Clinical Psychology*, 38(2), 113–154.
- Garety, P. A., & Freeman, D. (2013). The past and future of delusions research: From the inexplicable to the treatable. *The British Journal of Psychiatry*, 203(5), 327–333.
- Gayer-Anderson, C., Jongsma, H. E., Di Forti, M., Quattrone, D., Velthorst, E., & de Haan, L. (2019). The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) – Incidence and First-Episode Case-Control Programme. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services*. <https://doi.org/10.17863/CAM.47763>.
- González, L. E., López-Carrilero, R., Barrigón, M. L., Grasa, E., Barajas, A., Pousa, E. ... Ochoa, S. (2018). Neuropsychological functioning and jumping to conclusions in recent onset psychosis patients. *Schizophrenia Research*, 195, 366–371.
- Huq, S. F., Garety, P. A., & Hemsley, D. R. (1988). Probabilistic judgements in deluded and non-deluded subjects. *The Quarterly Journal of Experimental Psychology A: Human Experimental Psychology*, 40(4-A), 801–812.
- International Schizophrenia Consortium, Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., Sullivan, P. F., & Sklar, P. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*, 460(7256), 748–752.
- Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Mulè, A., Szöke, A. ... EU-GEI WP2 Group (2018). Treated incidence of psychotic disorders in the multinational EU-GEI study. *JAMA Psychiatry*, 75(1), 36–46.
- Langdon, R., Still, M., Connors, M. H., Ward, P. B., & Catts, S. V. (2014). Jumping to delusions in early psychosis. *Cognitive Neuropsychiatry*, 19(3), 241–256.
- Lincoln, T. M., Ziegler, M., Mehl, S., & Rief, W. (2010). The jumping to conclusions bias in delusions: Specificity and changeability. *Journal of Abnormal Psychology*, 119(1), 40–49.
- Loh, P.-R., Danecek, P., Palamara, P. F., Fuchsberger, C., A Reshef, Y., K Finucane, H. ... (2016). Reference-based phasing using the haplotype reference consortium panel. *Nature Genetics*, 48(11), 1443–1448.
- Lunt, L., Bramham, J., Morris, R. G., Bullock, P. R., Selway, R. P., Xenitidis, K., & David, A. S. (2012). Prefrontal cortex dysfunction and ‘jumping to conclusions’: Bias or deficit? *Journal of Neuropsychology*, 6(1), 65–78.
- Mallett, R. (1997). *Sociodemographic schedule*. London: Section of Social Psychiatry, Institute of Psychiatry.
- McCarthy, S., Das, S., Kretschmar, W., Delaneau, O., Wood, A. R., Teumer, A. et al. (2016). A reference panel of 64976 haplotypes for genotype imputation. *Nature Genetics*, 48(10), 1279–1283.
- McGuffin, P., Farmer, A., & Harvey, I. A. (1991). Polydiagnostic application of operational criteria in studies of psychotic illness: Development and reliability of the OPCRIT system. *Archives of General Psychiatry*, 48(8), 764–770.
- Menon, M., Pomarol-Clotet, E., McKenna, P. J., & McCarthy, R. A. (2006). Probabilistic reasoning in schizophrenia: A comparison of the performance of deluded and nondeluded schizophrenic patients and exploration of possible cognitive underpinnings. *Cognitive Neuropsychiatry*, 11(6), 521–536.
- Mistry, S., Harrison, J. R., Smith, D. J., Escott-Price, V., & Zammit, S. (2018). The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review. *Schizophrenia Research*, 197, 2–8.
- Moritz, S., Veckenstedt, R., Andreou, C., Bohn, F., Hottenrott, B., Leighton, L., ... Roesch-Ely, D. (2014). Sustained and “sleeper” effects of group metacognitive training for schizophrenia: A randomized clinical trial. *JAMA Psychiatry*, 71(10), 1103–1111.
- Moritz, S., Veckenstedt, R., Bohn, F., Hottenrott, B., Scheu, F., Randjbar, S., ... Roesch-Ely, D. (2013). Complementary group metacognitive training (MCT) reduces delusional ideation in schizophrenia. *Schizophrenia Research*, 151(1), 61–69.
- Moritz, S., & Woodward, T. S. (2005). Jumping to conclusions in delusional and non-delusional schizophrenic patients. *British Journal of Clinical Psychology*, 44(2), 193–207.
- Moutoussis, M., Bentall, R. P., El-Deredy, W., & Dayan, P. (2011). Bayesian modelling of jumping-to-conclusions bias in delusional patients. *Cognitive Neuropsychiatry*, 16(5), 422–447.
- Ochoa, S., López-Carrilero, R., Barrigón, M. L., Pousa, E., Barajas, A., Lorente-Rovira, E., ... Moritz, S. (2017). Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis. *Psychological Medicine*, 47(9), 1573–1584.
- Oh, K., Sumiyoshi, C., Fujino, H., Yasuda, Y., Yamamori, H., Fujimoto, M., ... Hashimoto, R. (2018). Genetic overlap between general cognitive function and schizophrenia: A review of cognitive GWASs. *International Journal of Molecular Sciences*, 19(12), 3822.
- Ormrod, J., Shaftoe, D., Cavanagh, K., Freeston, M., Turkington, D., Price, J., & Dudley, R. (2012). A pilot study exploring the contribution of working memory to “jumping to conclusions” in people with first episode psychosis. *Cognitive Neuropsychiatry*, 17(2), 97–114.
- Peters, E., & Garety, P. (2006). Cognitive functioning in delusions: A longitudinal analysis. *Behaviour Research and Therapy*, 44(4), 481–514.
- Preacher, K. J., & Hayes, A. F. (2008). Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behavior Research Methods*, 40(3), 879–891.
- Quattrone, D., Di Forti, M., Gayer-Anderson, C., Ferraro, L., Jongsma, H. E., Tripoli, G., ... Reininghaus, U. (2018). Transdiagnostic dimensions of psychopathology at first episode psychosis: Findings from the multinational EU-GEI study. *Psychological Medicine*, 49(8), 1–14.
- Reininghaus, U., Rauschenberg, C., ten Have, M., de Graaf, R., van Dorsselaer, S., Simons, C. J. P., ... van Os, J. (2018). Reasoning bias, working memory performance and a transdiagnostic phenotype of affective disturbances and psychotic experiences in the general population. *Psychological Medicine*, 49(11), 1799–1809.
- Rodriguez, V., Ajnakina, O., Stilo, S. A., Mondelli, V., Marques, T. R., Trotta, A., ... Murray, R. M. (2018). Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: The GAP study. *Psychological Medicine*, 49(13), 1–11.

- Ross, R. M., McKay, R., Coltheart, M., & Langdon, R. (2015). Jumping to conclusions about the beads task? A meta-analysis of delusional ideation and data-gathering. *Schizophrenia Bulletin*, *41*(5), 1183–1191.
- Savage, J. E., Jansen, P. R., Stringer, S., Watanabe, K., Bryois, J., de Leeuw, C. A., *et al.* (2018). Genome-wide association meta-analysis in 269867 individuals identifies new genetic and functional links to intelligence. *Nature Genetics*, *50*(7), 912–919.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature*, *511*(7510), 421–427.
- Shafee, R., Nanda, P., Padmanabhan, J. L., Tandon, N., Alliey-Rodriguez, N., Kalapurakel, S., ... Robinson, E. B. (2018). Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. *Translational Psychiatry*, *8*(1), 78.
- Smoller, J. W., Andreassen, O. A., Edenberg, H. J., Faraone, S. V., Glatt, S. J., & Kendler, K. S. (2019). Psychiatric genetics and the structure of psychopathology. *Molecular Psychiatry*, *24*(3), 409–420.
- So, S. H.-W., Siu, N. Y.-F., Wong, H.-L., Chan, W., & Garety, P. A. (2016). 'Jumping to conclusions' data-gathering bias in psychosis and other psychiatric disorders – Two meta-analyses of comparisons between patients and healthy individuals. *Clinical Psychology Review*, *46*, 151–167.
- StataCorp (2017). *Stata statistical software: Release 15*. College Station, TX: StataCorpLLC.
- Stefanis, N. C., Hanssen, M., Smirnis, N. K., Avramopoulos, D. A., Evdokimidis, I. K., Stefanis, C. N., ... van Os, J. (2002). Evidence that three dimensions of psychosis have a distribution in the general population. *Psychological Medicine*, *32*(2), 347–358.
- Touloupoulou, T., Zhang, X., Cherny, S., Dickinson, D., Berman, K. F., Straub, R. E., ... Weinberger, D. R. (2018). Polygenic risk score increases schizophrenia liability through cognition-relevant pathways. *Brain*, *142*(2), 471–485.
- Van Dael, F., Versmissen, D., Janssen, I., Myin-Germeys, I., van Os, J., & Krabbendam, L. (2005). Data gathering: Biased in psychosis? *Schizophrenia Bulletin*, *32*(2), 341–351.
- Vassos, E., Di Forti, M., Coleman, J., Iyegbe, C., Prata, D., Euesden, J., ... Breen, G. (2017). An examination of polygenic score risk prediction in individuals with first-episode psychosis. *Biological Psychiatry*, *81*(6), 470–477.
- Velthorst, E., Levine, S. Z., Henquet, C., de Haan, L., van Os, J., Myin-Germeys, I., & Reichenberg, A. (2013). To cut a short test even shorter: Reliability and validity of a brief assessment of intellectual ability in schizophrenia – a control-case family study. *Cognitive Neuropsychiatry*, *18*(6), 574–593.
- Woodward, T. S., Mizrahi, R., Menon, M., & Christensen, B. K. (2009). Correspondences between theory of mind, jumping to conclusions, neuro-psychological measures and the symptoms of schizophrenia. *Psychiatry Research*, *170*(2–3), 119–123.
- Wray, N. R., Lee, S. H., Mehta, D., Vinkhuyzen, A. A. E., Dudbridge, F., & Middeldorp, C. M. (2014). Research review: Polygenic methods and their application to psychiatric traits. *Journal of Child Psychology and Psychiatry*, *55*(10), 1068–1087.
- Wykes, T., Newton, E., Landau, S., Rice, C., Thompson, N., & Frangou, S. (2007). Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: An exploratory randomized controlled trial. *Schizophrenia Research*, *94*(1), 221–230.